A Case Series of Refractory Pediatric Atopic Dermatitis Effectively Treated With Dupilumab in Combination With Abrocitinib.

Autor: Fong WCG; Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK., Kaung HHW; Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Lopes R; Department of Paediatric Dermatology, St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.; St Thomas' NHS Foundation Trust, London, UK., Kanji A; Department of Paediatric Dermatology, St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.; St Thomas' NHS Foundation Trust, London, UK.; Paediatric and Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London, London, UK., Ravenscroft J; Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.; Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Tang TS; Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.; Department of Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Flohr C; Department of Paediatric Dermatology, St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.; St Thomas' NHS Foundation Trust, London, UK.; Paediatric and Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London, London, UK.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.
DOI: 10.1111/pde.15761
Abstrakt: Children with severe atopic dermatitis (AD), refractory to conventional systemic treatment as well as single-agent biologic and Janus kinase inhibitor (JAKi) such as abrocitinib, currently face a lack of treatment options. In response to this clinical conundrum, we present three cases of severe and refractory pediatric AD successfully managed with combined dupilumab and abrocitinib. These children had exhausted all conventional treatments and had undergone treatment with both dupilumab and abrocitinib individually, as well as dupilumab in conjunction with methotrexate. It was only when the combination of dupilumab and abrocitinib was introduced that they finally achieved noticeable and sustained improvements in disease control.
(© 2024 The Author(s). Pediatric Dermatology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: